TenX Keane Acquisition
Status: Live Deal
U=S+R
R=S/5
IPO Proceeds, $M | $66.00M |
---|---|
IPO Date | Oct 14, 2022 |
CEO | Xiaofeng Yuan |
Left Lead | Maxim |
IPO Cash in Trust | 102.0% |
SPAC Tenor | 9 + 3 + 3 + 10 |
IPO Sector |
General
Asia (excluding China, Hong Kong and Macau) |
IPO Geography | Asia |
Target Company | Citius Pharmaceuticals, Inc. |
Deal Announced | Oct 24, 2023 |
Deal Size, $M | TBD |
Deal Sector | Healthcare |
Deal Geography | US/Canada |
SEC Filings | www.sec.gov |
Approval Vote | TBD |
Amendment Vote | Jan 17, 2024 |
TENK
TENKU
TENKR
Price | $11.13 |
---|---|
Last closing price | $11.11 |
H/L, today | $11.13 / $11.13 |
H/L, 52-week | $9.62 / $10.91 |
Volume, today | 388 |
Volume, 3-month avg. | N/A |
Price | $12.61 |
---|---|
Last closing price | $12.61 |
High/low price, today | $12.55 / $12.61 |
High/low price, 52-week | $10.08 / $12.40 |
Volume, today | 452 |
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Price | $0.23 |
---|---|
Last closing price | $0.19 |
High/low price, today | $0.22 / $0.25 |
High/low price, 52-week | $0.10 / $8.83 |
Volume, today | 7,270 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on TenX Keane Acquisition:
- Structure and cap table
- 5 directors & officers
- 19 filings and events
- 1 underwriters
- 2 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Xiaofeng Yuan | 50 | CEO, Chairman |
Taylor Zhang | 42 | CFO and Director |
Cathy Jiang | 32 | Director |
Joel Mayersohn | 63 | Director |
Brian Hartzband | 36 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
Maxim | BR | 6,000,000 | units |
6,000,000 | units | ||
Up-Front UW fee | 2.00 | % |
Sign in to view more advisor data.
Filings
Sign in to view 19 filings.